• Explore /
  • Poster
  • / A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC).

A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC).

Abstract Poster

Authors

null

Aiwu Ruth He

Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC

Aiwu Ruth He , Alexander Y. Kim , Beau M Toskich , Kabir Mody , Kevin Kim , Stacey Stein , Lipika Goyal , Thomas Adam Abrams , Daniel Brown , Laura Williams Goff , Richard D. Kim , Nainesh Parikh , Tyler Sandow , Daniel Johnson , Renuka V. Iyer , Michael Petroziello , Smitha S. Krishnamurthi , Charles Martin , Yixing Jiang , Nabeel Akhter

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session: Hepatobiliary Cancer

Track

Hepatobiliary Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04541173

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr TPS358)

DOI

10.1200/JCO.2021.39.3_suppl.TPS358

Abstract #

TPS358

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Aiwu Ruth He

First Author: Daneng Li

First Author: Aaron Scott Mansfield

Poster

2023 ASCO Gastrointestinal Cancers Symposium

A phase I clinical trial of stereotactic body radiotherapy with atezolizumab and bevacizumab in advanced hepatocellular carcinoma.

A phase I clinical trial of stereotactic body radiotherapy with atezolizumab and bevacizumab in advanced hepatocellular carcinoma.

First Author: Timothy J Brown